Population Pharmacokinetics and Pharmacodynamics of Chloroquine in aPlasmodium vivaxVolunteer Infection Study
Azrin N Abd-Rahman, Louise Marquart, Nathalie Gobeau, Anne Kummel, Julie A Simpson, Stephan Chalon, Jorg J Mohrle, James S McCarthy
Clinical Pharmacology & Therapeutics | WILEY | Published : 2020
Chloroquine has been used for the treatment of malaria for > 70 years; however, chloroquine pharmacokinetic (PK) and pharmacodynamic (PD) profile in Plasmodium vivax malaria is poorly understood. The objective of this study was to describe the PK/PD relationship of chloroquine and its major metabolite, desethylchloroquine, in a P. vivax volunteer infection study. We analyzed data from 24 healthy subjects who were inoculated with blood-stage P. vivax malaria and administered a standard treatment course of chloroquine. The PK of chloroquine and desethylchloroquine was described by a two-compartment model with first-order absorption and elimination. The relationship between plasma and whole blo..View full abstract
Awarded by Australian National Health and Medical Research Council Senior Research Fellowship
Awarded by Australian Centre for Research Excellence in Malaria Elimination - NHMRC
This study was funded by Medicines for Malaria Venture (MMV). MMV is funded by a number of donors including USAID, Bill and Melinda Gates Foundation, UK Department for International Development, Norwegian Agency for Development Cooperation, Irish Aid, Newcrest Mining Limited, Australian Aid, Swiss Agency For Development and Co-Operation, and Wellcome Trust. These funders had no role in the design, conduct, or analysis of the trial. J.S.M. was supported by an Australian National Health and Medical Research Foundation Practitioner Fellowship. J.A.S. is funded by an Australian National Health and Medical Research Council Senior Research Fellowship 1104975. This work was supported in part by the Australian Centre for Research Excellence in Malaria Elimination, funded by the NHMRC (1134989).